Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-105123
Filing Date
2025-08-07
Accepted
2025-08-07 16:35:23
Documents
67
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q avir-20250630.htm   iXBRL 10-Q 2649663
2 EX-31.1 avir-ex31_1.htm EX-31.1 15653
3 EX-31.2 avir-ex31_2.htm EX-31.2 15883
4 EX-32.1 avir-ex32_1.htm EX-32.1 11056
5 EX-32.2 avir-ex32_2.htm EX-32.2 10370
  Complete submission text file 0000950170-25-105123.txt   9084969

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT avir-20250630.xsd EX-101.SCH 1012218
70 EXTRACTED XBRL INSTANCE DOCUMENT avir-20250630_htm.xml XML 1709850
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39661 | Film No.: 251194773
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)